Dyne Therapeutics, Inc. announced on 2nd December 2021 the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug …
Dyne Therapeutics announce application to start exon 51 skipping clinical trialRead More

December 7, 2021 by Lynnette
Dyne Therapeutics, Inc. announced on 2nd December 2021 the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug …
Dyne Therapeutics announce application to start exon 51 skipping clinical trialRead More

December 16, 2019 by Neil
Sarepta Therapeutics has announced that the FDA (the medicines regular in the US) has granted accelerated approval to golodirsen. Golodirsen, or …

December 5, 2019 by Lynnette
We've welcomed over 100 people to our Science on Tour events throughout 2019, these empowering and invaluable sessions have been a huge success and we …

September 19, 2019 by Neil
Wave Life Sciences announced earlier this week that Suvodirsen has been granted fast track approval by the Federal Drug Administration (the drug …

August 9, 2019 by Neil
In recent press releases, Sarepta Therapeutics has given updates on their ongoing clinical trial programmes. These include exon skipping and gene …
Action Duchenne
5th Floor, Mariner House
62 Prince Street
Bristol
BS1 4QD
07535 498 506
info@actionduchenne.org
